Atherosclerosis Cardiovascular DiseasePhase 2NCT07422051
Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis
A Phase 2 study testing Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose in people with Atherosclerosis Cardiovascular Disease, run by Spanish National Research Council at 1 site in Spain.
Trial summary
The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Atherosclerosis Cardiovascular Disease
- What is being tested?
- Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteSpain
- Study dates
- 21 Feb 2026to 30 Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18 to 40 years.
- Male or female volunteers.
- Healthy individuals with no diagnosed diseases.
- Normal-weight participants with a Body Mass Index (BMI) between 18.5 and 24.9 kg/m².
- Ability to provide voluntary informed consent.
- Willingness to comply with all study procedures.
- Availability to participate in the two-phase selection process, including initial screening and subsequent laboratory tests.
Who cannot join
- Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances.
- Current use of any medication, except hormonal contraceptives.
- Pregnant or breastfeeding women.
- Participation in a clinical trial with an investigational product within the last 60 days, or current enrolment in a clinical trial.
- Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Instituto de la Grasa-CSIC
Seville, 41013
Javier Perona S. Perona, PhD, +34954611550, perona@ig.csic.es
About this study
The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:
Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?
Read more
Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.
Participants will:
Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol
Undergo serial postprandial assessments over several hours, including:
Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events
Read the detailed description
The present project builds on previous studies in which we suggested that erythrodiol, a bioactive component of pomace olive oil, is capable of helping prevent cardiovascular diseases when administered as part of pomace oil, through the inhibition of atherosclerosis development.
A total of 22 adult volunteers, both women and men (18-40 years old), healthy and of normal weight, will be selected. Participants will be recruited in two phases.
In the first phase, recruitment will take place at Pablo de Olavide University. Inclusion criteria for this phase include: age between 18 and 40 years; body mass index (BMI) between 18.5 and 24.9 kg/m²; ability to provide informed voluntary consent; and willingness to comply with all study procedures. Candidates will be excluded if, at the time of recruitment, they exhibit any of the following: presence of any type of pathology (digestive, metabolic, endocrine, infectious, neoplastic, etc.) or food-related allergies or intolerances. Individuals taking any type of medication-except contraceptives-will also be excluded, as well as pregnant or breastfeeding women, and anyone who has participated in a clinical trial involving an investigational product within the past 60 days or is currently enrolled in a clinical trial. Furthermore, any person with a physical or intellectual limitation that, in the investigator's opinion, could prevent adherence to and completion of the protocol will be excluded. In this phase, only clinical history, age, weight, and height data will be collected.
In the second phase, only those subjects whose complete biochemical and hematological analyses produce results within normal ranges will be included in the study.
At the Virgen del Rocío Hospital (Seville), and after a 12-hour fast, three experiments will be conducted. In each of them, participants will be administered pomace olive oil containing different concentrations (low, medium, or high) of erythrodiol, the protective agent, in an amount of 50 g on each occasion. On the study day, blood samples will be taken (between 6 and 24 mL per draw and 90 mL total), 15 minutes before (baseline) and every hour for 6 hours after ingestion of a meal rich in the corresponding pomace oil. The meal will be accompanied by coffee (black, without sugar) or skimmed milk and whole-grain toast (3 slices). The consumption of these foods carries no health risk.
Venous access will be obtained by puncture with an Abbocath® catheter fitted with a Smartsite™ valve (Ivac®, Spec-Sets®) and a Vacutainer® system for sterile Hemogard® tubes with a silicone separator. This procedure involves only the risks inherent to simple blood sampling.
Part of the collected samples will be processed at the Clinical Analysis Laboratory Service of the Virgen del Rocío University Hospital for biochemical analysis, while another portion will be sent to the Instituto de la Grasa-CSIC.
In addition to these analyses, participants will undergo simple anthropometric measurements (weight, height, hip and waist circumference) as well as blood pressure assessment.
This procedure will be repeated after four weeks with a second oil, and four weeks later with the third one, so that all participants will have consumed all three oils.
- Conditions
- Atherosclerosis Cardiovascular Disease
- Being tested
- Low erythrodiol dose, Medium erythrodiol dose, High erythrodiol dose
- Keywords
- Randomized postprandial crossover trial, Erythrodiol, Pomace olive oil, Atherosclerosis, Macrophages
- Medical subject headings
- Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low erythrodiol doseOther
Low erythrodiol dose
Medium erythrodiol doseOther
Medium erythrodiol dose
High erythrodiol doseOther
High erythrodiol dose
| Study group | Role | What they receive |
|---|---|---|
| Low erythrodiol | Active comparator | Not described Receives: Other: Low erythrodiol dose |
| Medium erythrodiol | Active comparator | Not described Receives: Other: Medium erythrodiol dose |
| High erythrodiol | Active comparator | Not described Receives: Other: High erythrodiol dose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma erythrodiol concentration
Measured: 4 months since the last intervention session
Secondary outcomes (2)
Plasma triglyceride concentration
Measured: 4 months since the last intervention session
Inflammation marker concentration in plasma
Measured: 4 months since the last intervention session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start21 Feb 2026 (estimated)
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atherosclerosis Cardiovascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This study uses a randomized, postprandial, crossover interventional design, in which each participant receives all three test conditions (low, medium, and high erythrodiol doses) in separate visits. Participants act as their own controls, and each intervention is separated by a washout period of 4 weeks to avoid carry-over effects.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 22 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Spanish National Research Council
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Javier Sanchez Perona, Spanish National Research Council
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07422051
- Sponsor's protocol ID
- ORIVA24041961
- Status last verified
- Feb 2026
- First submitted
- 10 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis
- ClinicalTrials.gov ID
- NCT07422051
- Acronym / sponsor ID
- ORIVA24041961
- Conditions
- Atherosclerosis Cardiovascular Disease
- Keywords
- Randomized postprandial crossover trial, Erythrodiol, Pomace olive oil, Atherosclerosis, Macrophages
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 22 participants (estimated)
- Lead sponsor
- Spanish National Research CouncilOther government
- Study start
- 21 Feb 2026 (estimated)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:
Is erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?
Researchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.
Participants will:
Attend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol
Undergo serial postprandial assessments over several hours, including:
Blood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events
Detailed description
The present project builds on previous studies in which we suggested that erythrodiol, a bioactive component of pomace olive oil, is capable of helping prevent cardiovascular diseases when administered as part of pomace oil, through the inhibition of atherosclerosis development.
A total of 22 adult volunteers, both women and men (18-40 years old), healthy and of normal weight, will be selected. Participants will be recruited in two phases.
In the first phase, recruitment will take place at Pablo de Olavide University. Inclusion criteria for this phase include: age between 18 and 40 years; body mass index (BMI) between 18.5 and 24.9 kg/m²; ability to provide informed voluntary consent; and willingness to comply with all study procedures. Candidates will be excluded if, at the time of recruitment, they exhibit any of the following: presence of any type of pathology (digestive, metabolic, endocrine, infectious, neoplastic, etc.) or food-related allergies or intolerances. Individuals taking any type of medication-except contraceptives-will also be excluded, as well as pregnant or breastfeeding women, and anyone who has participated in a clinical trial involving an investigational product within the past 60 days or is currently enrolled in a clinical trial. Furthermore, any person with a physical or intellectual limitation that, in the investigator's opinion, could prevent adherence to and completion of the protocol will be excluded. In this phase, only clinical history, age, weight, and height data will be collected.
In the second phase, only those subjects whose complete biochemical and hematological analyses produce results within normal ranges will be included in the study.
At the Virgen del Rocío Hospital (Seville), and after a 12-hour fast, three experiments will be conducted. In each of them, participants will be administered pomace olive oil containing different concentrations (low, medium, or high) of erythrodiol, the protective agent, in an amount of 50 g on each occasion. On the study day, blood samples will be taken (between 6 and 24 mL per draw and 90 mL total), 15 minutes before (baseline) and every hour for 6 hours after ingestion of a meal rich in the corresponding pomace oil. The meal will be accompanied by coffee (black, without sugar) or skimmed milk and whole-grain toast (3 slices). The consumption of these foods carries no health risk.
Venous access will be obtained by puncture with an Abbocath® catheter fitted with a Smartsite™ valve (Ivac®, Spec-Sets®) and a Vacutainer® system for sterile Hemogard® tubes with a silicone separator. This procedure involves only the risks inherent to simple blood sampling.
Part of the collected samples will be processed at the Clinical Analysis Laboratory Service of the Virgen del Rocío University Hospital for biochemical analysis, while another portion will be sent to the Instituto de la Grasa-CSIC.
In addition to these analyses, participants will undergo simple anthropometric measurements (weight, height, hip and waist circumference) as well as blood pressure assessment.
This procedure will be repeated after four weeks with a second oil, and four weeks later with the third one, so that all participants will have consumed all three oils.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
- Model description
- This study uses a randomized, postprandial, crossover interventional design, in which each participant receives all three test conditions (low, medium, and high erythrodiol doses) in separate visits. Participants act as their own controls, and each intervention is separated by a washout period of 4 weeks to avoid carry-over effects.
| Arm | Type | Receives |
|---|---|---|
| Low erythrodiol | Active comparator | Other: Low erythrodiol dose |
| Medium erythrodiol | Active comparator | Other: Medium erythrodiol dose |
| High erythrodiol | Active comparator | Other: High erythrodiol dose |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Adults aged 18 to 40 years.
- Male or female volunteers.
- Healthy individuals with no diagnosed diseases.
- Normal-weight participants with a Body Mass Index (BMI) between 18.5 and 24.9 kg/m².
- Ability to provide voluntary informed consent.
Key exclusion criteria (5 listed)
- Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances.
- Current use of any medication, except hormonal contraceptives.
- Pregnant or breastfeeding women.
- Participation in a clinical trial with an investigational product within the last 60 days, or current enrolment in a clinical trial.
- Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low erythrodiol doseLow erythrodiol dose | Other | Low erythrodiol |
| Medium erythrodiol doseMedium erythrodiol dose | Other | Medium erythrodiol |
| High erythrodiol doseHigh erythrodiol dose | Other | High erythrodiol |
Primary outcome
Plasma erythrodiol concentration
Time frame: 4 months since the last intervention session
2 secondary outcomes
Plasma triglyceride concentration
Time frame: 4 months since the last intervention session
Inflammation marker concentration in plasma
Time frame: 4 months since the last intervention session
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Atherosclerosis Cardiovascular Disease
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Low erythrodiol dose, Medium erythrodiol dose and High erythrodiol dose in people with Atherosclerosis Cardiovascular Disease, run by Spanish National Research Council at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Javier Perona S. Perona, PhD (34954611550, perona@ig.csic.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma erythrodiol concentration (time frame: 4 months since the last intervention session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.